Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) 2.0
version of its patented DehydraTECH(TM) oral drug-delivery technology has
demonstrated its power to deliver more cannabidiol (“CBD”) into the bloodstream
than generic industry-control formulations (http://ibn.fm/Utl7A). An article discussing the company
reads, “The company’s 2.0 technology is specifically being developed for
effectiveness in helping to deliver its drug payload across the blood-brain
barrier, a natural biological system of blood vessels and endothelial cells
that bar most drugs from accessing the brain’s central-nervous-system
hierarchy. The ability to effectively deliver drugs to the brain is of keen
interest to developers of drugs designed to beneficially target the central
nervous system. . . . Lexaria’s research and development showed that
DehydraTECH version 2.0 was able to deliver 1,937% more CBD into brain tissue
than generic industry-control formulations and 487% more than the original
DehydraTECH technology, according to the company’s news release.”
To view the full article, visit http://ibn.fm/5tKhB
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery
platforms. The company’s patented DehydraTECH drug-delivery technology changes
the way active pharmaceutical ingredients enter the bloodstream, promoting
healthier ingestion methods, lower overall dosing and higher effectiveness for
lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time
of onset and masks unwanted tastes for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to
multiple companies in the cannabis industry for use in cannabinoid beverages,
edibles and oral products, as well as to a world-leading tobacco producer for
the development of smokeless, oral-based nicotine products. Lexaria operates a
licensed, in-house research laboratory and holds a robust intellectual property
portfolio with 16 patents granted and over 60 patents pending worldwide. For
more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks
website applicable to all content provided by QS, wherever published or
re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment